厄他培南、庆大霉素、磷霉素与头孢曲松治疗肛门生殖器淋病的疗效(NABOGO):一项随机非劣效性试验
在荷兰阿姆斯特丹性健康中心开展的随机、对照、双盲、非劣效性试验纳入346例成人肛门生殖器淋病患者,按1:1:1:1随机接受头孢曲松500 mg、厄他培南1000 mg、庆大霉素5 mg/kg(最大400 mg)或磷霉素6 g。符合方案分析中,厄他培南对头孢曲松的风险差为-0.01(95%CI -0.08至0.05),达到非劣效;庆大霉素风险差为-0.07(95%CI -0.16至-0.01),未达到非劣效;磷霉素组因中期分析显示疗效低于60%而提前终止。
要点
- 单剂厄他培南1000 mg对单剂头孢曲松500 mg在肛门生殖器淋病治疗中达到非劣效。
- 庆大霉素5 mg/kg(最大400 mg)对头孢曲松未达到非劣效。
- 磷霉素组因中期分析显示疗效低于60%而提前终止。
核心结论
- 单剂1000 mg厄他培南对单剂500 mg头孢曲松在淋病治疗中达到非劣效。
- 5 mg/kg庆大霉素(最大400 mg)对头孢曲松未达到非劣效。
- 厄他培南是肛门生殖器淋奈瑟菌感染潜在的有效替代方案,值得针对头孢曲松耐药感染进行评估。
研究设计与样本
- 在荷兰阿姆斯特丹性健康中心开展的随机、对照、双盲、非劣效性试验,设三个试验组和一个对照组。
- 纳入18岁及以上、患有肛门直肠或泌尿生殖道淋病的成人。
- 采用随机排列区组按1:1:1:1随机分配至肌内注射头孢曲松500 mg(对照组)、肌内注射厄他培南1000 mg、肌内注射庆大霉素5 mg/kg(最大400 mg)或口服磷霉素6 g。
- 主要分析为符合方案分析(排除失访者),改良意向性分析将失访者视为治疗失败。
- 2017年9月18日至2020年6月5日,从2160例受邀患者中分配346例(16%)参与者。
主要发现
- 符合方案分析中,头孢曲松组93/93例(100%)、厄他培南组86/87例(99%)、庆大霉素组79/85例(93%)、磷霉素组4/33例(12%)清除淋奈瑟菌。
- 符合方案分析中,厄他培南对头孢曲松的风险差为-0.01(95%CI -0.08至0.05),庆大霉素对头孢曲松的风险差为-0.07(95%CI -0.16至-0.01)。
- 改良意向性分析中,厄他培南对头孢曲松的风险差为-0.08(95%CI -0.17至0.003),庆大霉素对头孢曲松的风险差为-0.11(95%CI -0.21至-0.04)。
- 至少发生一次不良事件的患者比例:厄他培南组58/103例(56%)、磷霉素组36/38例(95%)、头孢曲松组24/103例(23%)。
- 磷霉素组在中期分析显示疗效低于60%后提前终止。
关键数值与推荐
- 非劣效性判定标准为:试验组与对照组差异的下侧Hochberg校正95%CI大于-10%。
- 主要结局为治疗后7-14天预定义主要感染部位核酸扩增检测阴性的参与者比例。
- 厄他培南组与头孢曲松组风险差-0.01(95%CI -0.08至0.05),下侧95%CI大于-10%,达到非劣效。
- 庆大霉素组与头孢曲松组风险差-0.07(95%CI -0.16至-0.01),未达到非劣效。
临床怎么用
- 单剂1000 mg厄他培南对单剂500 mg头孢曲松在淋病治疗中达到非劣效。
- 5 mg/kg庆大霉素(最大400 mg)对头孢曲松未达到非劣效。
- 作者认为厄他培南是肛门生殖器淋奈瑟菌感染潜在的有效替代方案,值得针对头孢曲松耐药感染进行评估。
局限性
- 磷霉素组在中期分析显示疗效低于60%后提前终止。
- 作者认为厄他培南值得针对头孢曲松耐药感染进行评估,提示需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Neisseria gonorrhoeae causes gonorrhoea, a common sexually transmitted infection. Emerging strains resistant to first-line ceftriaxone threaten N gonorrhoeae management. Hence, alternative treatments are needed. We aimed to evaluate the efficacy of ertapenem, gentamicin, and fosfomycin as alternative treatments for anogenital N gonorrhoeae. METHODS: In a randomised, controlled, double-blind, non-inferiority trial (three experimental groups and one control group) at the Centre for Sexual Health in Amsterdam, Netherlands, we included adults aged 18 years or older, with anorectal or urogenital gonorrhoea. With random permuted blocks, participants were randomly assigned (1:1:1:1) to receive intramuscular 500 mg ceftriaxone (control group), intramuscular 1000 mg ertapenem, intramuscular 5 mg/kg gentamicin (maximum 400 mg), or oral 6 g fosfomycin. The primary outcome was the proportion of participants with a negative nucleic acid amplification test of the predefined primary infected site, 7-14 days after treatment. The primary analysis was per protocol (ie, excluding those lost to follow-up). The modified intention-to-treat analysis included all randomly assigned patients with anogenital gonorrhoea considering those lost-to-follow-up as treatment failure. Non-inferiority was established if the lower Hochberg-corrected 95% CI for difference between the experimental and control groups was greater than -10%. For the analysis of adverse events, we included all participants who received medication. The trial was registered at ClinicalTrials.gov (NCT03294395) and is complete. FINDINGS: Between Sept 18, 2017, and June 5, 2020, from 2160 patients invited to participate, we assigned 346 (16%) participants to receive either ceftriaxone (n=103), ertapenem (n=103), gentamicin (n=102), or fosfomycin (n=38). The fosfomycin group was terminated early after interim analysis revealed less than 60% efficacy. In the primary per-protocol analysis, 93 (100%) of 93 patients in the ceftriaxone group, 86 (99%) of 87 patients in the ertapenem group, 79 (93%) of 85 patients in the gentamicin group, and four (12%) of 33 patients in the fosfomycin group cleared N gonorrhoeae (risk difference vs ceftriaxone -0·01 [95% CI -0·08 to 0·05] for ertapenem and -0·07 [-0·16 to -0·01] for gentamicin). Thus, ertapenem proved non-inferior to ceftriaxone. In mITT analysis, risk differences versus ceftriaxone were -0·08 (-0·17 to 0·003) for ertapenem and -0·11 (-0·21 to -0·04) for gentamicin. We observed a higher proportion of patients with at least one adverse event in the ertapenem group (58 [56%] of 103) and fosfomycin group (36 [95%] of 38) versus the ceftriaxone group (24 [23%] of 103). INTERPRETATION: Single-dose 1000 mg ertapenem is non-inferior to single-dose 500 mg ceftriaxone in gonorrhoea treatment. Yet, 5 mg/kg gentamicin (maximum 400 mg) is not non-inferior to ceftriaxone. Ertapenem is a potential effective alternative for anogenital N gonorrhoeae infections and merits evaluation for ceftriaxone-resistant infections. FUNDING: ZonMw and GGD-Amsterdam. TRANSLATION: For the Dutch translation of the abstract see Supplementary Materials section.
引用
- de Vries HJC, de Laat M, Jongen VW, et al. Efficacy of ertapenem, gentamicin, fosfomycin, and ceftriaxone for the treatment of anogenital gonorrhoea (NABOGO): a randomised, non-inferiority trial. Lancet Infect Dis. 2022. PMID: 35065063. doi:10.1016/S1473-3099(21)00625-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。